Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic

Core Insights - Basilea Pharmaceutica Ltd has announced a partnership with Phare Bio Inc. to leverage AI for antibiotic discovery, addressing the urgent need for new antibiotics in the face of antimicrobial resistance [1][2][3] Company Overview - Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company focused on developing innovative drugs for severe bacterial and fungal infections, with two successful hospital brands, Cresemba and Zevtera, already launched [5] - Phare Bio Inc. is a biotech social venture founded in 2020, utilizing AI to develop novel antibiotics and backed by organizations like The Audacious Project and Google.org [4] Partnership Details - The partnership will utilize Phare Bio's Generative AI platform to design antibacterial molecules that meet specific medical and commercial criteria, with Basilea responsible for further development [2] - Phare Bio will receive success-based payments upon achieving predefined milestones, marking a new model for antibiotic innovation that combines technological advances with industrial expertise [2][3] Strategic Importance - The collaboration is seen as a significant step in combating antimicrobial resistance, aligning AI-driven drug discovery with a commitment to developing innovative antibiotics [3] - Both companies emphasize the importance of addressing public health crises through innovative drug development and collaboration [3]